Literature DB >> 12786606

Review article: medical treatment of severe ulcerative colitis.

F Rizzello1, P Gionchetti, A Venturi, M Campieri.   

Abstract

Severe colitis is a life-threatening complication of ulcerative colitis. Early recognition of the severity of the colitis and intensive treatment and monitoring have all contributed to improved outcome. Since their introduction in 1950s, corticosteroids are the first line therapy for severe active ulcerative colitis (UC). Several prognostic parameters (such as stools movement per day, C-reactive protein, increased amount of intestinal gas or small bowel dilation, hypoalbuminemia, fever etc) help the physician to quickly introduce cyclosporin or to refer the patient to the surgeon. This decision requires a careful evaluation of the patient and a medical /surgical team. Infliximab seems to be a promising drug but more controlled trial are needed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12786606     DOI: 10.1046/j.1365-2036.17.s2.18.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis.

Authors:  Makoto Ooi; Shin Nishiumi; Tomoo Yoshie; Yuuki Shiomi; Michitaka Kohashi; Ken Fukunaga; Shiro Nakamura; Takayuki Matsumoto; Naoya Hatano; Masakazu Shinohara; Yasuhiro Irino; Tadaomi Takenawa; Takeshi Azuma; Masaru Yoshida
Journal:  Inflamm Res       Date:  2011-04-27       Impact factor: 4.575

2.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

3.  Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.

Authors:  Jin Li; Cheng Chen; Xiao-Nian Cao; Gui-Hua Wang; Jun-Bo Hu; Jing Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-02-06

4.  Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.

Authors:  Elham A Hassan; Haidi K Ramadan; Ali A Ismael; Khaled F Mohamed; Madiha M El-Attar; Ihab Alhelali
Journal:  Saudi J Gastroenterol       Date:  2017 Jul-Aug       Impact factor: 2.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.